- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BAUDAX BIO Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MPH HEALTH CARE | 17,800 | -0,84 % | Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH): Kaufen | Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH
18.09.2025 / 16:25 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| SOLIGENIX | 1,685 | 0,00 % | SOLIGENIX, INC.: Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma | FLASH 2 Study Interim Efficacy Analysis Targeted for 1H2026 Enrollment Update Remains on Track for 4Q2025 PRINCETON, N.J., Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq:... ► Artikel lesen | |
| CHARLOTTES WEB | 0,140 | -4,76 % | Charlotte's Web Holdings, Inc.: Charlotte's Web Reports Year-Over-Year Growth For Q2 2025 | Second Consecutive Quarter of Year-over-Year Revenue Growth Supported by New Product Innovations and Omnichannel Expansion
LOUISVILLE, Colo., Aug. 13, 2025 ... ► Artikel lesen | |
| QUALIGEN THERAPEUTICS | 3,240 | -100,00 % | Qualigen Therapeutics, Inc.: Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For? | Carlsbad, CA, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the "Company") today announced the official launch of C10 Cryptocurrency Asset Treasury (DAT) purchases:... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 1,620 | +0,28 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress | - Late Breaking Abstract to Present Additional Data from Aclaris' Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 1,225 | 0,00 % | NovaBay Pharmaceuticals: CEO David Lazar tritt nach Aktienübertragungsvereinbarung zurück | ||
| ALLARITY THERAPEUTICS | 1,590 | 0,00 % | Allarity Therapeutics, Inc.: Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer | TARPON SPRINGS, Fla., August 26, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib-a... ► Artikel lesen | |
| AVENUE THERAPEUTICS | 0,454 | 0,00 % | NSE - AVENUE THERAPEUTICS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| BIOSTAR PHARMACEUTICALS | - | - | Biostar Pharma, Inc.: The FDA Granted Orphan Drug Designation to Biostar Pharma's Utidelone for the Treatment of Pancreatic Cancer | SAN FRANCISCO, Sept. 25, 2025 /PRNewswire/ -- Biostar Pharma, Inc., the US wholly-owned subsidiary of Beijing Biostar Biopharmaceutical Co., Ltd. ("Biostar,"... ► Artikel lesen | |
| APTORUM GROUP | 1,655 | 0,00 % | Aptorum Group Ltd: As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives | NEW YORK, NY, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical... ► Artikel lesen | |
| PETROS PHARMACEUTICALS | 0,066 | 0,00 % | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position | NEW YORK, NY / ACCESS Newswire / June 25, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the... ► Artikel lesen | |
| PROCESSA PHARMACEUTICALS | 0,373 | 0,00 % | Why Processa Pharmaceuticals Stock Rose Almost 38% Overnight? | ||
| PAINREFORM | 1,280 | -11,11 % | PainReform Ltd: PainReform Provides Business Update for the Six Months Ended June 30, 2025 | TEL AVIV, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a specialty pharmaceutical company focused on the reformulation of established therapeutics and commercialization... ► Artikel lesen | |
| CDT EQUITY | - | - | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS20678X3044 CDT Equity Inc. 10.10.2025 US20678X4034 CDT Equity Inc. 13.10.2025 Tausch 8:1US5381461012 LivePerson... ► Artikel lesen | |
| BAYER | 27,840 | -0,50 % | Krebsforschung mit Milliarden-Potenzial: So könnten Bayer, Vidac Pharma und BioNTech ins Spiel kommen | Der Onkologie-Markt brummt wie kaum ein anderer. Getrieben von technologischen Quantensprüngen und leider auch steigenden Fallzahlen, entwickelt sich die Krebsbehandlung zum lukrativen Innovationsmotor.... ► Artikel lesen |
Das Unternehmen BAUDAX BIO INC kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BAUDAX BIO INC finden Sie auf Wallstreet Online.